- Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category
- The ADRIQ rewards Quebec-based companies for leadership in innovation in their respective fields
- Earlier this year, the company received the F.D.A.’s fast-track designation for TH1902 for the treatment of advanced and recurrent solid tumors expressing the sortilin receptor
- Theratechnologies commercializes two medicines in HIV and has research programs in NASH, oncology and HIV
- Theratechnologies (TH) closed down by 1.86 per cent trading at $4.21 per share
Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.
The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective fields.
At the beginning of 2021, Theratechnologies received the F.D.A.’s fast-track designation for TH1902 for the treatment of advanced and recurrent solid tumors expressing the sortilin receptor.
TH1902 is a peptide-drug conjugate derived from the company’s oncological SORT1+ technology. It combines a proprietary peptide with docetaxel.
The company’s research has been partially funded by The Canadian Cancer Society and the government of Quebec.
Paul Lévesque, President and CEO of Theratechnologies, stated,
“It is quite rare to obtain the fast-track designation this early in the drug development process and this was achieved through spectacular preclinical data. We are very proud of this achievement and look forward to the future with great hope for patients.”
The 31st ADRIQ Innovation Awards Gala was held on November 25, 2021.
Theratechnologies commercializes two medicines in HIV and has research programs in NASH, oncology and HIV.
Theratechnologies (TH) closed down by 1.86 per cent trading at $4.21 per share.
